Exchanges
BSE, NSE
Industry
Pharmaceuticals
Issue
Book building

Rubicon Research IPO

₹628.20

+29.53% on listing

Listing-day close · NSE · 16 Oct 2025 · issue price ₹485

Rubicon Research’s ₹1,377 crore IPO was priced at ₹485 a share. It listed on the NSE on 16 Oct 2025 and closed its first day at ₹628.20, up 29.53% on the issue price.

Timeline

  1. Opens
  2. Closes
  3. Allotment
  4. Refunds
  5. Shares in demat
  6. Listing

Issue details

Issue size
₹1,377 Cr
Fresh issue
₹500 Cr
Offer for sale
₹877 Cr
Lot size
30 shares
Minimum investment
₹14,550
Face value
₹1
Registrar
MUFG Intime India

Subscription

Rubicon Research IPO subscription by investor category
CategoryShares offeredTimes subscribed
Total—60.38×

Overall, from the basis of allotment.

Financials and valuation

Market cap (post-issue)
₹7,990 Cr
P/E (post-issue)
46.1
EPS (post-issue)
₹10.51
Price to book
13.7
ROE
29.02%
ROCE
26.45%
Debt to equity
0.73
EBITDA margin
20.67%
PAT margin
10.37%
Promoter holding
75.71% → 59.78%

Financials as of 31 Mar 2025, from the offer documents.

Listing

Listing date
16 Oct 2025
Issue price
₹485
Open
₹620.00
High
₹639.00
Low
₹587.35
Close
₹628.20

Listing day on the NSE. The close was +29.53% on the issue price.

RUBICON RESEARCH share price today

FAQs

When did the Rubicon Research IPO open and close?

It opened on 9 Oct 2025 and closed on 13 Oct 2025.

What was the Rubicon Research IPO price?

The price band was ₹461–485 a share. The final issue price was ₹485.

What is the lot size and minimum investment?

One lot is 30 shares, ₹14,550 at ₹485 a share. Retail investors apply in whole lots.

How much did Rubicon Research raise?

₹1,377 crore: ₹500 crore of new shares and ₹877 crore offered by existing shareholders.

How many times was the Rubicon Research IPO subscribed?

60.38 times overall.

How did Rubicon Research list?

It listed on the NSE on 16 Oct 2025 at ₹620.00 and closed the day at ₹628.20, up 29.53% on the ₹485 issue price.

Who is the registrar of the Rubicon Research IPO?

MUFG Intime India handles the allotment, refunds and credit of shares.

For information only. Not investment advice or a research report.

Full disclaimer

See how an IPO fits your plan

Armor checks every holding against your goals, risk and timeline.

Get the app